CITI/CALL/MODERNA/270/0.1/20.06.24 Stock

CITI/CALL/MODERNA/270/0.1/20.06.24 Share Price

Warrant

DE000KG5X8R5

End-of-day quote Deutsche Boerse AG
- ^EUR	-

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart MODERNA, INC.

Chart CITI/CALL/MODERNA/270/0.1/20.06.24

Latest news about MODERNA, INC.

Argus Raises Moderna's Price Target to $150 From $115	07:54pm	MT
Squamous Cell Carcinoma Pipeline 2024 \| FDA Approvals, Clinical Trials, Therapies, MOA, ROA \| Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna	06-19	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA	06-15	PR
FDA asks COVID vaccine makers to target KP.2 strain with updated shots	06-14	RE

More news

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	MODERNA, INC.
Issuer	Citi
WKN	KG5X8R
ISIN	DE000KG5X8R5
Date issued	25/07/2022
Strike	270 $
Maturity	Today (-0 Days)
Parity	10 : 1
Emission price	2.98 €
Emission volume	N/A
Settlement	Por diferencias
Currency	EUR

Technical Indicators

Delta	0x
Omega	0.000000
Premium	0x
Gearing	0x
Moneyness	0.4936
Difference Strike	135.1 $
Difference Strike %	+50.02%
Intrinsic value	0.000000

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).

Sector

More about the company